Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Clinical trial NCT04136782 · RECRUITING
Trial details
- NCT number
- NCT04136782
- Sponsor
- Shengjing Hospital
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-19
- Primary completion
- 2025-11-30
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.